Navigation Links
All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
Date:5/26/2011

enotype 1 subjects;
  • PSI-7977 400mg QD and BMS-790052 60mg QD for 24 weeks in genotype 2 or 3 subjects;
  • PSI-7977 400mg QD, BMS-790052 60mg QD and ribavirin for 24 weeks in genotype 1 subjects;
  • PSI-7977 400mg QD, BMS-790052 60mg QD and ribavirin for 24 weeks in genotype 2 or 3 subjects.

  • Additional details can be found at www.clinicaltrials.gov.

    About Pharmasset

    Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in three Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, recently reported safety and efficacy data from 14-days of monotherapy as well as 14 days in combination with the pyrimidine, PSI-7977. An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin third quarter 2011. Mericitabine (RG7128) continues in two Phase 2b trials and one interferon-free trial conducted through a strategic collaboration with Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    Office: +1 (609) 865-0693

    Forward-Looking Statements

    Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform
    '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
    2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
    3. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
    4. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
    5. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
    6. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
    7. Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
    8. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
    9. New Interim Data About Combination Oral Contraceptives
    10. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
    11. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... 2015  Legendary actor and director Danny Glover ... campaign designed to educate and encourage patients with neurologic ... Affect (PBA) and to speak with their physician. The ... the ability to cry and laugh on cue and ... by people living with PBA episodes. While ...
    (Date:5/1/2015)... 2015  Misonix, Inc. (NASDAQ: MSON ), ... and markets innovative therapeutic ultrasonic products for spine ... laparoscopic surgery and other surgical applications, announced today ... third quarter fiscal year 2015 on Thursday, May ... call that same day, Thursday, May 7, 2015, ...
    (Date:4/30/2015)... April 30, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular ... highlights and financial results for the fiscal year ... herein are in Canadian dollars unless otherwise stated. ... significant, with the right strategic partners and additional ...
    Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6
    ... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA), a ... consummated two separate transactions to acquire all the online ... medications, diabetics supplies, and medical equipment, and merge with ... "The combination will bring together two companies committed ...
    ... and INGELHEIM, Germany, Feb. 15, 2011 Pfenex ... the Pfenex Expression Technology™ platform and Boehringer Ingelheim ... leader in biopharmaceutical contract development and manufacture, announced ... agreement. It provides Boehringer Ingelheim with non-exclusive access ...
    Cached Medicine Technology:HealthWarehouse.com Acquires Online Division of Hocks Pharmacy 2Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 2Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 3
    (Date:5/4/2015)... 2015 Fast on the heels of ... Amounts, and Allison Folmar, JD, join over 150 speakers ... , On Sunday, May 24, the conference presents "I ... Are you interested in Ryan Hinds' recovery story? The ... war against autism was written by Marcia Hinds, ...
    (Date:5/4/2015)... Sara Soulati, CEO of Global ... in Los Angeles associated with the field of Enhanced ... The Sara Soulati Health For Life Program (SSHFLP). , ... lifestyle modification and disease prevention program. A provisional ... S. Patents and Trademarks Office and is now under ...
    (Date:5/3/2015)... May 03, 2015 Leading international program ... it will be awarding the 2015 Harris Wofford Global ... Selemawit Ghebrendrias, are the deserving recipients of the award ... service, Harris Llewellyn Wofford. The two recipients were chosen ... for global health. , CFHI is one of ...
    (Date:5/3/2015)... CA (PRWEB) May 03, 2015 NuevaCare ... MnemeTherapy® at two upcoming area seminars. The first event ... PSA Annual Regional Stroke Conference to be held at ... offered on Wednesday, May 13 during the Dementia Conference ... , “These seminars offer an excellent opportunity to ...
    (Date:5/2/2015)... NV (PRWEB) May 02, 2015 Ticket Down ... tickets for the long awaited event today, Saturday, May ... Diehard boxing fans will be able to secure tickets ... , The fight that boxing fans have wanted for more ... months ago. Floyd “Money” Mayweather will step inside the ring ...
    Breaking Medicine News(10 mins):Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3
    ... suggests that the presence of tumor cells in the circulating ... and neck may predict disease recurrence and reduced survival. An ... a worse outcome. Those are the early ... of CTCs by a team of researchers at The Ohio ...
    ... , TUESDAY, Dec. 21 (HealthDay News) -- Certain ... fat, according to an animal study that might one day ... tests on mice, a team at the Joslin Diabetes Center ... caused progenitor cells in subcutaneous (just beneath the skin) white ...
    ... with locally advanced head and neck cancers who successfully ... so without losing the ability to speak clearly and ... Institute. "This is good news," said Joseph K. ... Duke and the corresponding author of the study. "I ...
    ... robotic surgery for upper airway and digestive track malignant ... techniques based on patient function and survival, according to ... neck squamous cell carcinomas account for about 4 percent ... year. Currently the standard minimally invasive surgery for these ...
    ... HealthDay Reporter , MONDAY, Dec. 20 (HealthDay News) ... for strict heart rate control in patients with atrial ... strokes. More lenient management of the condition is ... guidelines from the American College of Cardiology and the ...
    ... , MONDAY, Dec. 20 (HealthDay News) -- ... swallow after undergoing combined chemotherapy and radiation treatment, but ... have found. The new study included patients who ... treated with chemoradiotherapy for advanced head and neck cancer. ...
    Cached Medicine News:Health News:Tumor cells in blood may signal worse prognosis in head and neck cancer patients 2Health News:Factors linked to speech/swallowing problems after treatment for head and neck cancers 2Health News:Robotic surgery for head and neck cancer shows promise 2Health News:Guidelines Eased for Patients With Irregular Heartbeats 2Health News:Guidelines Eased for Patients With Irregular Heartbeats 3Health News:Speech, Swallowing Usually OK After Head & Neck Cancer Therapy 2